Germany · Delayed Price · Currency is EUR FamiCord AG Company Description
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally.
It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties.
It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells.
In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials.
The company was formerly known as VITA 34 AG and changed its name to FamiCord AG in February 2025. FamiCord AG was founded in 1997 and is based in Leipzig, Germany.
| Country | Germany |
| Founded | 1997 |
| Industry | Medical Care Facilities |
| Sector | Healthcare |
| Employees | 771 |
| CEO | Jakub Baran |
Contact Details
Address: Perlickstrasse 5 Leipzig, 04103 Germany | |
| Phone | 49 341 48792 5500 |
| Website | famicord.com |
Stock Details
| Ticker Symbol | V3V |
| Exchange | Deutsche Börse Xetra |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | DE000A0BL849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jakub Julian Baran | Chairman of the Management Board and Chief Executive Officer |
| Tomasz Franciszek Baran | Vice President of the Management Board and CMO |
| Thomas Pfaadt | Chief Financial Officer and Member of Management Board |
| Dr. Conelia Wittke-Kothe | CCO and Member of Management Board |
| Santiago Luengo | Managing Director of Secuvita |